Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment of juvenile rheumatoid arthritis

  • Kim, Kwang-Nam (Department of Pediatrics, Hangang Sacred Heart Hospital, School of Medicine Hallym University)
  • Received : 2010.10.09
  • Accepted : 2010.10.19
  • Published : 2010.11.15
Download PDF
⟨ Previous Next ⟩

Abstract

The systematic approach to pharmacologic treatment is typically to begin with the safest, simplest, and most conservative measures. It has been realized that the more rapidly inflammation is under control, the less likely it is that there will be permanent sequelae. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of initial treatment for inflammation. In addition, the slow-acting antirheumatic drugs (SAARDs) and disease-modifying antirheumatic drugs (DMARDs) have efficacy of anti-inflammatory action in children with chronic arthritis. New therapeutic modalities for inflammation, such as etanercept and infliximab, promise even further improvements in the risk/benefit ratio of treatment. It is not typically possible at the onset of the disease to predict which children will recover and which will go on to have unremitting disease with lingering disability or enter adulthood with serious functional impairment. Therefore, the initial therapeutic approach must be vigorous in all children.

Keywords

References

  1. Cassidy JT, Petty RE. Textbook of pediatric rheumatology. 5th ed. Philadelphia : WB Saunders Co, 2006:231-60.
  2. Keenan GF, Giannini EH, Athreya BH. Clinically significant gastropathy associated with nonsteroidal anti-inflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol 1995;22:1149-51.
  3. Kiss MH, Reiff AA, Reicin AS. Rofecoxib demonstrates efficacy and tolerability in children and adolescent with juvenile rheumatoid arthritis in a 12 week randomized study. Arthritis Rheum 2003;48 Suppl 9:S650.
  4. Cassidy JT. Medical management of children with juvenile rheumatoid arthritis. Drugs 1999;58:831-50. https://doi.org/10.2165/00003495-199958050-00006
  5. Levy ML, Barron KS, Eichenfield A. Naproxen-induced pseudo-porphyria: a distinctive photodermatitis. J Pediatr 1990;117:660-4. https://doi.org/10.1016/S0022-3476(05)80710-3
  6. Makla AL, Lempiainem M, Ylijoki H. Ibuprofen levels in serum and synovial fluid. Scand J Rheumatol Suppl 1981;39:15-7.
  7. Dowd JE, Cimaz R, Fink CW. Nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in children. Arthritis Rheum 1995;38:1225-31. https://doi.org/10.1002/art.1780380908
  8. Allen RC, Petty RE, Lirenman DS, Malleson PN, Laxer RM. Renal papillary necrosis in children with chronic arthritis. Am J Dis Child 1986;140:20-2.
  9. Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003;88:197-200. https://doi.org/10.1136/adc.88.3.197
  10. Kugathasan S, Newman AJ, Dahms BB, Boyle JT. Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving long-term effect of methotrexate therapy. J Pediatr 1996;128:149-51. https://doi.org/10.1016/S0022-3476(96)70448-1
  11. Cron RQ, Sherry DD, Wallace CA. Methotrexate-induced hyper-sensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr 1998;132:901-2. https://doi.org/10.1016/S0022-3476(98)70331-2
  12. Michels H. What is low-dose corticosteroid therapy in juvenile idiopathic arthritis? A worldwide, questionnaire-based survey. Z Rheumatol 2000;59 Suppl 2:II/127-30. https://doi.org/10.1007/s003930070008
  13. Falcini F, Taccetti G, Trapani S, Tafi L, Volpi M. Growth retardation in juvenile chronic arthritis patients treated with steroids. Clin Exp Rheumatol 1991;9 Suppl 6:S37-40.
  14. Adebajo AO, Hall MA. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheumatol 1998;37:1240-2. https://doi.org/10.1093/rheumatology/37.11.1240
  15. Ilowite NT. Update on biologics in juvenile idiopathic arthritis. Curr Opin Rheumatol 2008;20:613-8. https://doi.org/10.1097/BOR.0b013e3283060778
  16. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:496-504.
  17. Lovell DJ, Ruperto N, Goodman S. Adalimumab is safe and effective during Long-term treatment of patients with juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:s292.
  18. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al; Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20. https://doi.org/10.1056/NEJMoa0706290
  19. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91. https://doi.org/10.1016/S0140-6736(08)60998-8
  20. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Periz N, Silva CA, et al. Long-term safety and efficacy of Abatacept in children with juvenile idiopathic arthritis. Arthitis Rheum 2010;62:1792-802. https://doi.org/10.1002/art.27431
  21. Ruperto N, Lovell DJ, Cuttica R. Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106. https://doi.org/10.1002/art.22838
  22. Coto C, Varela G, Hernandez V. Use of recombinant interferon gamma in pediatric patients with advanced juvenile chronic arthritis. Biotherapy 1998;11:15-20. https://doi.org/10.1023/A:1007932130188
  23. Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009;28:129-37. https://doi.org/10.1007/s10067-008-0995-9
  24. Lovell DJ, Giannini EH, Kimura Y. Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:S514.
  25. Yokota s, Kishimoto T. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis. Expert Rev Clin Immunol 2010;6:735-43. https://doi.org/10.1586/eci.10.41
  26. Lehman TJ, Striegel KH, Onel KB. Thalidomide thrapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr 2002;140:125-7. https://doi.org/10.1067/mpd.2002.120835
  27. Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996;128:275-8. https://doi.org/10.1016/S0022-3476(96)70408-0
  28. Grondin C, Malleson P, Petty RE. Slow acting antirheumatic drugs in chronic arthritis of childhood. Semin Arthritis Rheum 1988;18:38-47. https://doi.org/10.1016/0049-0172(88)90033-9
  29. Wulffraat N, van Royen A, Bierings M, Vossen J, Kuis W. Autologous haemopoietic stem cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet 1999;353:550-3. https://doi.org/10.1016/S0140-6736(98)05399-9
  30. Haines KA. Juvenile Idiopathic Arthritis: Therapies in the 21st century. Bull NYU Hosp Jt Dis 2007;65:205-11.
  31. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol 2008;27:67-76. https://doi.org/10.1007/s10067-008-0936-7

Cited by

  1. Juvenile Rheumatoid Arthritis in Children with Ebstein-barr Virus Infection vol.19, pp.1, 2010, https://doi.org/10.4078/jrd.2012.19.1.19
  2. Cervical fracture from chronic steroid usage presenting as a stroke: A case report vol.28, pp.None, 2010, https://doi.org/10.1016/j.ijscr.2016.09.042
  3. Developing and Evaluating JIApp: Acceptability and Usability of a Smartphone App System to Improve Self-Management in Young People With Juvenile Idiopathic Arthritis vol.5, pp.8, 2017, https://doi.org/10.2196/mhealth.7229
  4. 소아 특발성 관절염의 한약치료에 대한 문헌 고찰 vol.32, pp.4, 2010, https://doi.org/10.7778/jpkm.2018.32.4.024
  5. 소아 류마티스 관절염으로 인한 경피증에 대한 한방복합치료 증례보고 1례 vol.33, pp.4, 2010, https://doi.org/10.7778/jpkm.2019.33.4.26
  6. Characterizing pain flares in adolescent inflammatory and non‐inflammatory musculoskeletal disorders: A qualitative study using an interpretative phenomenological approach vol.24, pp.9, 2020, https://doi.org/10.1002/ejp.1626
  7. Juvenile idiopathic arthritis in Jordan: single center experience vol.19, pp.1, 2021, https://doi.org/10.1186/s12969-021-00572-8